Patients with locally advanced pancreatic cancer who have previously received standard first-line anti-tumor treatment (radiotherapy, chemotherapy, targeted or immunotherapy, etc.)
Locally advanced pancreatic cancer is defined as follows: a. The tumor has no distant metastasis; b. Pancreatic head/uncinate process: The tumor contacts the superior mesenteric artery \>180˚; c. Pancreatic body and tail: The tumor contacts the superior mesenteric artery or celiac artery \>180˚; The tumor contacts the celiac artery and infiltrates the abdominal aorta; d. The tumor invades the jejunal branch of the superior mesenteric artery. Portal vein-superior mesenteric vein cannot be safely reconstructed due to tumor invasion, vein occlusion, or involvement of a large range of jejunal branches of the superior mesenteric vein.
At least one measurable lesion (RECIST1.1)
ECOG PS 0-1
Expected survival time\>3 months
Adequate organ function
You may not be if
Malignant diseases other than pancreatic cancer diagnosed within 5 years before the first dose (excluding radically resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ)
Currently participating in interventional clinical research treatment, or having received other research drugs or used research devices within 4 weeks before the first dose
Active autoimmune disease
Allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation
Allergic to the active ingredients or excipients of this study drug, cadonilimab, S-1 or capecitabine
Have not fully recovered from any toxicity and/or complications caused by the intervention before starting treatment
History of HIV
Active HBV or HCV
Pregnant or breastfeeding women
Any severe or uncontrolled systemic disease
Active pulmonary tuberculosis
People with mental disorders who are unable to cooperate with treatment
Uncontrolled infection
The investigators assess that the subjects are unable to complete the entire trial process or are otherwise unsuitable for participating in this trial
Clareo Health | Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
